SCHEMBL1132524

SCHEMBL1132524

CC(C)(CCCCl)C(=O)O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACLY P53396 1/20 0.54
ACACB O00763 1/20 0.52
ACACA Q13085 1/20 0.52
PPARA Q07869 11/20 0.44
TTR P02766 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2C8 P10632 1/20 0.42
CHRM1 P11229 1/20 0.42
CYP2C9 P11712 1/20 0.42
TSHR P16473 1/20 0.42
ADRA1A P35348 1/20 0.42
PPARG P37231 1/20 0.42
HTR2B P41595 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
SLCO1B3 Q9NPD5 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
CISD1 Q9NZ45 1/20 0.42
SLCO1B1 Q9Y6L6 1/20 0.42
TBXAS1 P24557 3/20 0.40
GUCY1A1 Q02108 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6275324 0.98 ACLY (0.52) ACLYACACBACACAPPARATTR
SCHEMBL10870601 0.93 ACLY (0.57) ACLYACACBACACAPPARATTR
SCHEMBL28527574 0.91 ACLY (0.61) ACLYACACBACACAPPARATTR
SCHEMBL10869779 0.91 ACLY (0.61) ACLYACACBACACAPPARATTR
SCHEMBL10869000 0.91 ACLY (0.61) ACLYACACBACACAPPARATTR
SCHEMBL10872185 0.91 ACLY (0.61) ACLYACACBACACAPPARATTR
SCHEMBL350605 0.84
SCHEMBL7222208 0.84 ACLY (0.70) ACLYACACBACACAPPARATTR
SCHEMBL2784372 0.84 ACLY (0.62) ACLYACACBACACAPPARATTR
SCHEMBL2989709 0.82 ACLY (0.47) ACLYACACBACACAPPARATTR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105669368-B The preparation method of high-purity low colourity Gemfibrozil Capsules 浙江精进药业有限公司 2018-02-06 CN claimed
US-4665226-A Process for preparing 5-(2,5-dimethylphenoxy)-2,2-dimethylpentanoic acid WARNER-LAMBERT COMPANY (US) 1987-05-12 US claimed
CN-111728962-B Resveratrol derivative and medical application thereof in resisting fibrosis 绍兴君科臻元医药科技有限公司 2024-04-30 CN disclosed
WO-2020212955-A1 PROCESS FOR THE PREPARATION OF A KEY INTERMEDIATE OF GEMFIBROZIL HIKAL LIMITED (IN) 2020-10-22 WO disclosed
WO-2019069321-A1 AN IMPROVED PROCESS FOR THE PREPARATION OF A KEY INTERMEDIATE OF GEMFIBROZIL HIKAL LIMITED (IN) 2019-04-11 WO disclosed
EP-1812381-B1 ETHYLENICALLY UNSATURATED GROUP-CONTAINING ISOCYANATE COMPOUND AND PROCESS FOR PRODUCING THE SAME, AND REACTIVE MONOMER, REACTIVE (METH)ACRYLATE POLYMER AND ITS USE SHOWA DENKO KK (JP) 2011-02-16 EP disclosed
US-7579066-B2 Ethylenically unsaturated group-containing isocyanate compound and process for producing the same, and reactive monomer, reactive (meth) acrylate polymer and its use SHOWA DENKO K.K. (JP) 2009-08-25 US disclosed
US-20080132597-A1 Ethylenically Unsaturated Group-Containing Isocyanate Compound and Process for Producing the Same, and Reactive Monomer, Reactive (Meth) Acrylate Polymer and its Use RESONAC CORPORATION (JP) 2008-06-05 US disclosed
EP-0807627-B1 Anilide compounds as ACAT inhibitors KOWA CO (JP) 2005-12-28 EP disclosed
US-6825223-B2 ACYL COENZYME A CHOLESTEROL ACYLTRANSFERASE (ACAT) INHIBITORS; 2-SUBSTITUTED BENZIMIDAZOLE, BENZOXAZOLE, AND BENZOTHIAZOLES KOWA COMPANY, LTD. (JP) 2004-11-30 US disclosed
US-20020037910-A1 Novel anilide compounds and pharmaceutical compositions comprising them SHIBUYA KIMIYUKI (JP) 2002-03-28 US disclosed
EP-0807627-A2 Anilide compounds as ACAT inhibitors Kowa Company Ltd. (JP) 1997-11-19 EP disclosed
US-5641772-A Condensed diazepinones, processes for preparing them and agents containing these compounds for treating diseases of the central nervous system and for promoting cerebral blood circulation DR. KARL THOMAE GMBH (DE) 1997-06-24 US disclosed
US-5610155-A ALZHEIMER'S DR. KARL THOMAE GMBH (DE) 1997-03-11 US disclosed
EP-0226161-B1 IMPROVED PROCESS FOR PREPARING 5-(2,5-DIMETHYLPHENOXY)-2,2-DIMETHYLPENTANOIC ACID WARNER-LAMBERT COMPANY (US) 1989-11-08 EP disclosed
EP-0226161-A1 Improved process for preparing 5-(2,5-dimethylphenoxy)-2,2-dimethylpentanoic acid WARNER-LAMBERT COMPANY (US) 1987-06-24 EP disclosed
US-4665226-A Process for preparing 5-(2,5-dimethylphenoxy)-2,2-dimethylpentanoic acid WARNER-LAMBERT COMPANY (US) 1987-05-12 US disclosed
EP-0186083-A2 N-(2-Hyxdroxyalkyl)-amino acids and their derivatives, process for their preparation and pharmaceutical compositions containing them ASTA Pharma AG (DE) 1986-07-02 EP disclosed
EP-0103265-A2 Biphenylylpropionic acid derivative, process for preparing the same and pharmaceutical composition containing the same Kaken Pharmaceutical Co., Ltd. (JP) 1984-03-21 EP disclosed
US-4067726-A 3-Ureido phenylacetamide herbicides BAYER AKTIENGESELLSCHAFT (DT) 1978-01-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020037910-A1 Novel anilide compounds and pharmaceutical compositions comprising them ACAT1, LCAT, SOAT1 ACLY 204/4885ACACB 58/4885ACACA 43/4885
US-20080132597-A1 Ethylenically Unsaturated Group-Containing Isocyanate Compound and Process for Producing the Same, and Reactive Monomer, Reactive (Meth) Acrylate Polymer and its Use ACAD9, ELOVL6, ELOVL5 ACLY 206/4885ACACB 209/4885ACACA 168/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.